In this survey study of 2993 men in Australia, higher scores on the Medical Maximizing-Minimizing Scale, indicating stronger preferences for more health care, were associated with reduced relative risk of making an informed choice, having adequate conceptual and correct numerical knowledge of prostate cancer screening [...]
When men say “no” to treatment for prostate cancer, they don’t walk away feeling unburdened and free of concern. They’ve made a difficult decision and, as the diagnosis stays with them, they live with complex consequences.
Men who choose not to have recommended treatment for prostate cancer may avoid treatment-associated harms like incontinence and impotence, however our findings showed that the impact of the diagnosis itself is immense and far-reaching. A high priority for improving clinical practice is to ensure men [...]
Forty-one per cent of cancers detected by PSA screening can be classed as overdiagnosis, researchers say. Overdiagnosis of prostate cancer is a concern across the developed world, but researchers from Bond University say they are the first to quantify the problem in Australia.
More than 40 per cent of prostate cancers detected by basic screening tests are overdiagnosed in Australia, potentially leading to unnecessary treatments.
Professor Paul Glasziou, Bond University, says that we know that quite a lot of cancers are these dormant cancers that never would have disturbed the person in their lifetime... the most common complication would be impotence... Associate Professor David Smith, Cancer Council NSW, says we [...]
New Australian research suggests many men are being diagnosed with prostate cancer and potentially receiving unnecessary treatment. Bond University researchers have found too many men are getting invasive treatment, when more than 40 per cent of them wouldn't end up needing it.
The lifetime risk of being diagnosed with prostate cancer increased from 6.1% in 1982 (1 in 17) to 19.6% in 2012 (1 in 5). Using 2012 competing mortality rates, the lifetime risk in 1982 was 11.5% (95% CI 11.0% to 12.0%). The excess lifetime risk [...]
